Primary and secondary pulmonary hypertension in systemic lupus erythematosus

被引:81
作者
Pan, TLT [1 ]
Thumboo, J [1 ]
Boey, ML [1 ]
机构
[1] Tan Tock Seng Hosp, Dept Rheumatol & Immunol, Singapore 308433, Singapore
关键词
hypertension; pulmonary; Lupus erythematosus; systemic; Raynaud's phenomenon; Singapore;
D O I
10.1191/096120300678828361
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To describe the aetiology and clinical profile of primary and secondary pulmonary hypertension (PHT) in SLE patients. Methods: A retrospective study of SLE patients with PHT identified from a cohort of 786 SLE patients seen at Tan Tock Seng Hospital, Singapore. Results: 22 patients had primary and 24 patients had secondary PHT, with similar clinical features at presentation and a similar degree of pulmonary pressure elevation. Secondary PHT was due to valvular heart disease (50%), pulmonary embolism (13%), interstitial lung disease (8%) or a combination of these factors (29%). Primary PHT tended to present after a shorter duration of lupus than secondary PHT (8.8 vs 43.2 months, P = 0.118). At presentation, Raynaud's phenomenon was present in 34.8% of subjects with primary or secondary PHT. Among those with secondary PHT, the presence of Raynaud's phenomenon was associated with a trend towards higher pulmonary artery systolic pressures (51.0 vs 40.5 mmHg, P = 0.101). 17% of patients with PKT died, but from causes unrelated to PHT. Conclusion: Primary and secondary PI-IT are equally common in SLE patients. Secondary PHT is often multi-factorial, and Raynaud's phenomenon may be a marker for the severity of PKT in this group of patients.
引用
收藏
页码:338 / 342
页数:5
相关论文
共 16 条
[1]  
ASHERSON RA, 1990, J RHEUMATOL, V17, P1292
[2]  
ASHERSON RA, 1986, J RHEUMATOL, V13, P416
[3]   CARDIOVASCULAR MANIFESTATIONS IN SYSTEMIC LUPUS-ERYTHEMATOSUS - PROSPECTIVE-STUDY OF 100 PATIENTS [J].
BADUI, E ;
GARCIARUBI, D ;
ROBLES, E ;
JIMENEZ, J ;
JUAN, L ;
DELEZE, M ;
DIAZ, A ;
MINTZ, G .
ANGIOLOGY, 1985, 36 (07) :431-441
[4]  
GLADMAN DD, 1985, J RHEUMATOL, V12, P365
[5]  
Karmochkine M, 1996, J RHEUMATOL, V23, P286
[6]  
LAHITA RG, 1992, SYSTEMIC LUPUS ERYTH, P467
[7]  
MEDSGER TA, 1996, CLIN MANAGEMENT SYST, P89
[8]  
MURRAY JF, 1994, TXB RESPIRATORY MED, P693
[9]   PLEURO-PULMONARY MANIFESTATIONS OF SYSTEMIC LUPUS-ERYTHEMATOSUS - CLINICAL-FEATURES OF ITS SUBGROUPS - PROGNOSTIC AND THERAPEUTIC IMPLICATIONS [J].
PINES, A ;
KAPLINSKY, N ;
OLCHOVSKY, D ;
ROZENMAN, J ;
FRANKL, O .
CHEST, 1985, 88 (01) :129-135
[10]  
RICH A, 1997, HEART DIS TXB CARDIO, P780